why choose us

First received: July 25, 2023

Clinical Trial: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Study Status: Completed

Recruit Status: RECRUITING

Condition: Head and Neck Squamous Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Neoadjuvant Pembrolizumab and IO102-103 Prior to Curative-intent Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Brief Summary: This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN.This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103.In addition, participants will be monitored for any delays to their surgery due to the study drugs.

Read more